<p>Syndax Pharmaceuticals (SNDX) 在 ASH 会议上展示了最新的 Revuforj 数据，这一更新的疗效和安全性图景正是让投资者重新思考该股票长期潜力的原因。</p>
<p>请查看我们对 Syndax Pharmaceuticals 的最新分析。</p>
<p>在这一稳定的临床进展的推动下，该股票悄然重新定价，过去一个月的股价回报为 24.11%，年初至今的股价回报为 38.57%，尽管三年期的总股东回报仍为负值。这表明，随着投资者重新评估增长前景和风险特征，动能正在重建。</p>
<p>如果 Revuforj 的故事让你更广泛地关注肿瘤学和罕见疾病的股票，现在可能是探索其他潜在赢家的好时机。</p>
<p>然而，尽管 Revuforj 的临床验证不断增强，股价仍以大幅低于分析师目标的内在价值交易，Syndax 是否是一个被低估的成长故事，还是投资者已经将下一轮上涨的预期纳入考虑？</p>
<h2>最受欢迎的叙述：50.4% 被低估</h2>
<p>叙述的公允价值设定在接近 39 美元，而最后收盘价为 19.51 美元，这一差距突显了未来增长模型的激进性。</p>
<blockquote>
<p><em>晚期管线进展（包括前线试验、生命周期管理以及向新适应症如 Niktimvo 的 IPF 扩展），结合强劲的临床数据和在精准肿瘤学中的市场领先地位，提供了与对创新、靶向疗法需求激增相一致的强劲长期增长途径，支持持续的多年度盈利动能。</em></p>
</blockquote>
<p>阅读完整叙述。</p>
<p>想知道什么样的收入激增和利润重置能够证明这种上涨的合理性，以及未来的收益倍数如何将这一切联系在一起？完整的叙述对此进行了详细分析。</p>
<p><strong>结果：公允价值为 39.31 美元（被低估）</strong></p>
<p>完整阅读叙述，了解预测背后的原因。</p>
<p>然而，这一叙述依赖于 Revuforj 和 Niktimvo 的完美执行，安全性认知、标签延迟或更强的竞争对手可能迅速侵蚀这一上涨空间。</p>
<p>了解 Syndax Pharmaceuticals 叙述的关键风险。</p>
<h2>另一种看待价值的方式</h2>
<p>虽然叙述框架将 Syndax 标记为显著被低估，但简单的销售基础视角却讲述了一个截然不同的故事。该股票的销售倍数为 15.2 倍，而美国生物技术行业为 12.1 倍，同行为 11.1 倍，尤其是与仅 1.3 倍的公允比率相比，该股票看起来被高估了。</p>
<p>这一差距表明，投资者已经为未来的增长支付了丰厚的溢价。这引发了一个问题：这是一个定价错误的宝石，还是一个等待回调的拥挤动量交易？</p>
<p>查看数字对这一价格的看法——在我们的估值分析中了解更多。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55fa61da-ae1f-4d19-814f-da38552d6ebf/chart/ps-multiple-vs-industry?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55fa61da-ae1f-4d19-814f-da38552d6ebf/chart/ps-multiple-vs-industry"/></p>
<p>NasdaqGS:SNDX 截至 2025 年 12 月的 PS 比率</p>
<h2>自己构建 Syndax Pharmaceuticals 叙述</h2>
<p>如果这个视角与您的观点不符，或者您更愿意依赖自己的分析，您可以在三分钟内构建一个新的叙述：按照您的方式。</p>
<p>一个好的起点是我们的分析，强调投资者对 Syndax Pharmaceuticals 的两个关键回报的乐观预期。</p>
<h2>寻找更多投资想法？</h2>
<p>在市场充满定价错误的机会时，不要止步于一个引人注目的论点。使用这些专注的工具来提升您的下一步行动。</p>
<ul>
<li>通过扫描这些 3595 只财务状况良好的便士股票，尽早捕捉潜在的多倍收益，这些股票的股价微小，且资产负债表强劲，基本面改善。</li>
<li>通过瞄准这 26 只处于人工智能突破与可扩展商业模式交汇点的 AI 便士股票，乘势而上，享受结构性科技的顺风。</li>
<li>通过筛选这些 900 只被低估的股票，基于现金流的交易价格显著低于其内在价值估计，探索潜在的未来现金流引擎。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

Syndax制药

<p>Syndax 制药（SNDX）在 ASH 会议上展示了新的 Revuforj 数据，提升了投资者的兴趣，导致其股价在一个月内上涨了 24.11%。尽管三年回报为负，该股票被视为被低估，合理价值为 39.31 美元，而最后收盘价为 19.51 美元。叙述表明强劲的增长潜力，但也强调了安全感知和竞争等风险。该股票的高销售比率引发了对其估值的质疑。Simply Wall St 提供了分析，但不提供财务建议</p>

<p>Syndax Pharmaceuticals (SNDX) just put fresh Revuforj data center stage at the ASH meeting, and that updated efficacy and safety picture is exactly what has investors rethinking the stock’s longer term potential.</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals (SNDX) 在 ASH 会议上展示了最新的 Revuforj 数据，这一更新的疗效和安全性图景正是让投资者重新思考该股票长期潜力的原因。</p>
</div><p>See our latest analysis for Syndax Pharmaceuticals.</p>
<div class="lb-trans"><p>请查看我们对 Syndax Pharmaceuticals 的最新分析。</p>
</div><p>The stock has quietly rerated on the back of this steady clinical drumbeat, with a 1 month share price return of 24.11 percent and a year to date share price return of 38.57 percent, even though the 3 year total shareholder return remains negative. This suggests momentum is rebuilding as investors reassess both the growth runway and risk profile.</p>
<div class="lb-trans"><p>在这一稳定的临床进展的推动下，该股票悄然重新定价，过去一个月的股价回报为 24.11%，年初至今的股价回报为 38.57%，尽管三年期的总股东回报仍为负值。这表明，随着投资者重新评估增长前景和风险特征，动能正在重建。</p>
</div><p>If Revuforj’s story has you looking more broadly at oncology and rare disease names, it could be a good moment to explore other potential winners among healthcare stocks.</p>
<div class="lb-trans"><p>如果 Revuforj 的故事让你更广泛地关注肿瘤学和罕见疾病的股票，现在可能是探索其他潜在赢家的好时机。</p>
</div><p>Yet with shares still trading at a steep intrinsic discount to analyst targets despite Revuforj’s growing clinical validation, is Syndax an underappreciated growth story, or are investors already baking in the next leg of upside?</p>
<div class="lb-trans"><p>然而，尽管 Revuforj 的临床验证不断增强，股价仍以大幅低于分析师目标的内在价值交易，Syndax 是否是一个被低估的成长故事，还是投资者已经将下一轮上涨的预期纳入考虑？</p>
</div><h2>Most Popular Narrative Narrative: 50.4% Undervalued</h2>
<div class="lb-trans"><h2>最受欢迎的叙述：50.4% 被低估</h2>
</div><p>With the narrative fair value set near $39 against a last close of $19.51, the spread highlights how aggressively future growth is being modeled.</p>
<div class="lb-trans"><p>叙述的公允价值设定在接近 39 美元，而最后收盘价为 19.51 美元，这一差距突显了未来增长模型的激进性。</p>
</div><blockquote>
<p><em>Late-stage pipeline advancements (including frontline trials, lifecycle management, and expansion into new indications like IPF for Niktimvo), coupled with strong clinical data and market-leading positions in precision oncology, provide robust long-term growth avenues aligned with surging demand for innovative, targeted therapies, supporting sustained multi-year earnings momentum.</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>晚期管线进展（包括前线试验、生命周期管理以及向新适应症如 Niktimvo 的 IPF 扩展），结合强劲的临床数据和在精准肿瘤学中的市场领先地位，提供了与对创新、靶向疗法需求激增相一致的强劲长期增长途径，支持持续的多年度盈利动能。</em></p>
</blockquote>
</div><p>Read the complete narrative.</p>
<div class="lb-trans"><p>阅读完整叙述。</p>
</div><p>Curious what kind of revenue surge and margin reset could justify that kind of upside, and which future earnings multiple ties it all together? The full narrative breaks it down.</p>
<div class="lb-trans"><p>想知道什么样的收入激增和利润重置能够证明这种上涨的合理性，以及未来的收益倍数如何将这一切联系在一起？完整的叙述对此进行了详细分析。</p>
</div><p><strong>Result: Fair Value of $39.31 (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：公允价值为 39.31 美元（被低估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整阅读叙述，了解预测背后的原因。</p>
</div><p>However, the narrative hinges on flawless Revuforj and Niktimvo execution, where safety perceptions, label delays, or stronger competitors could quickly erode that upside.</p>
<div class="lb-trans"><p>然而，这一叙述依赖于 Revuforj 和 Niktimvo 的完美执行，安全性认知、标签延迟或更强的竞争对手可能迅速侵蚀这一上涨空间。</p>
</div><p>Find out about the key risks to this Syndax Pharmaceuticals narrative.</p>
<div class="lb-trans"><p>了解 Syndax Pharmaceuticals 叙述的关键风险。</p>
</div><h2>Another Way to Look at Value</h2>
<div class="lb-trans"><h2>另一种看待价值的方式</h2>
</div><p>While the narrative framework flags Syndax as significantly undervalued, a simple sales based lens tells a very different story. At 15.2 times sales versus 12.1 times for the US Biotechs industry and 11.1 times for peers, the stock looks stretched, especially against a fair ratio of just 1.3 times sales.</p>
<div class="lb-trans"><p>虽然叙述框架将 Syndax 标记为显著被低估，但简单的销售基础视角却讲述了一个截然不同的故事。该股票的销售倍数为 15.2 倍，而美国生物技术行业为 12.1 倍，同行为 11.1 倍，尤其是与仅 1.3 倍的公允比率相比，该股票看起来被高估了。</p>
</div><p>That gap suggests investors are already paying a rich premium for future growth. This raises the question: is this a mispriced gem or a crowded momentum trade waiting for a setback?</p>
<div class="lb-trans"><p>这一差距表明，投资者已经为未来的增长支付了丰厚的溢价。这引发了一个问题：这是一个定价错误的宝石，还是一个等待回调的拥挤动量交易？</p>
</div><p>See what the numbers say about this price — find out in our valuation breakdown.</p>
<div class="lb-trans"><p>查看数字对这一价格的看法——在我们的估值分析中了解更多。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55fa61da-ae1f-4d19-814f-da38552d6ebf/chart/ps-multiple-vs-industry" alt="" original-src="https://images.simplywall.st/company/55fa61da-ae1f-4d19-814f-da38552d6ebf/chart/ps-multiple-vs-industry"/></p>
<p>NasdaqGS:SNDX PS Ratio as at Dec 2025</p>
<div class="lb-trans"><p>NasdaqGS:SNDX 截至 2025 年 12 月的 PS 比率</p>
</div><h2>Build Your Own Syndax Pharmaceuticals Narrative</h2>
<div class="lb-trans"><h2>自己构建 Syndax Pharmaceuticals 叙述</h2>
</div><p>If this perspective does not line up with your own view, or you would rather lean on your own analysis, you can craft a fresh narrative in under three minutes: Do it your way.</p>
<div class="lb-trans"><p>如果这个视角与您的观点不符，或者您更愿意依赖自己的分析，您可以在三分钟内构建一个新的叙述：按照您的方式。</p>
</div><p>A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding Syndax Pharmaceuticals.</p>
<div class="lb-trans"><p>一个好的起点是我们的分析，强调投资者对 Syndax Pharmaceuticals 的两个关键回报的乐观预期。</p>
</div><h2>Looking for more investment ideas?</h2>
<div class="lb-trans"><h2>寻找更多投资想法？</h2>
</div><p>Do not stop with one compelling thesis when the market is full of mispriced opportunities. Use these focused tools to sharpen your next move.</p>
<div class="lb-trans"><p>在市场充满定价错误的机会时，不要止步于一个引人注目的论点。使用这些专注的工具来提升您的下一步行动。</p>
</div><ul>
<li>Capture potential multi baggers early by scanning these 3595 penny stocks with strong financials that already pair tiny share prices with balance sheet strength and improving fundamentals.</li>
<li>Ride structural tech tailwinds by targeting these 26 AI penny stocks positioned at the crossroads of artificial intelligence breakthroughs and scalable business models.</li>
<li>Explore potential future cash flow engines by filtering for these 900 undervalued stocks based on cash flows that trade at meaningful discounts to their intrinsic value estimates.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过扫描这些 3595 只财务状况良好的便士股票，尽早捕捉潜在的多倍收益，这些股票的股价微小，且资产负债表强劲，基本面改善。</li>
<li>通过瞄准这 26 只处于人工智能突破与可扩展商业模式交汇点的 AI 便士股票，乘势而上，享受结构性科技的顺风。</li>
<li>通过筛选这些 900 只被低估的股票，基于现金流的交易价格显著低于其内在价值估计，探索潜在的未来现金流引擎。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

Syndax 制药（SNDX）在主要血液学会议上发布强劲的新 Revuforj 数据后的估值分析